Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multimedia

Ajai Chari, MD
Conference Coverage
Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Michael R Green, PhD, The University of Texas MD Anderson Cancer Center, Houston, Texas
Conference Coverage
Emerging Role of Epigenetic Therapies in Follicular Lymphoma and DLBCL Treatment
02/15/2024

Featuring Michael R Green, PhD

Featuring Michael R Green, PhD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.
At the 2023 Lymphoma, Leukemia &...
02/15/2024
Lymphoma, Leukemia & Myeloma Network
Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024

Featuring Eliza A Hawkes, MD

Featuring Eliza A Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024

Featuring Suzanne Lentszch, MD, PhD

Featuring Suzanne Lentszch, MD, PhD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Asher Chanan-Khan, MD
Conference Coverage
Benefits of BCL-2 Targeting Treatment for Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Asher Chanan-Khan, MD

Featuring Asher Chanan-Khan, MD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia &...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Javier Pinilla-Ibarz, MD, PhD
Conference Coverage
Utilizing BTK Inhibitors to Treat Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Javier Pinilla-Ibarz, MD, PhD

Featuring Javier Pinilla-Ibarz, MD, P...
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma,...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Adriana Rossi, MD, Mount Sinai
Conference Coverage
CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma
01/24/2024

Featuring Adriana Rossi, MD

Featuring Adriana Rossi, MD
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023...
01/24/2024
Lymphoma, Leukemia & Myeloma Network
Dan Vogl, MD, University of Pennsylvania
Conference Coverage
Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma
01/23/2024

Featuring Dan Vogl, MD

Featuring Dan Vogl, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network
Faith E. Davies, MD, Perlmutter Cancer Center
Conference Coverage
Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma
01/22/2024

Featuring Faith E. Davies, MD

Featuring Faith E. Davies, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma,...
01/22/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

In the News

News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023

Jordan Kadish 

Jordan Kadish 
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma
06/26/2023

Jordan Kadish

Jordan Kadish
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and...
06/26/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023

Jordan Kadish

Jordan Kadish
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023

Jordan Kadish

Jordan Kadish
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology

Advertisement

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use